Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous Angiotensin II infusion in hypertensive patients

Blood Pressure

Volumn 11, Issue 4, 2002, Pages 244-252

  Fridman, Katarina U B ^a   Elmfeldt, Dag ^a   Wysocki, Marian ^a   Friberg, Peter R ^a   Andersson, Ove K ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin II infusion; Angiotensin II receptor blocker; Blood pressure; Filtration fraction; Hypertension; Renal vascular resistance

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; LOSARTAN POTASSIUM; PLACEBO; RENIN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; DRUG DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE; VALINE;

ADRENERGIC RECEPTOR BLOCKING; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE RESPONSE; HUMAN; KIDNEY BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VASOCONSTRICTION; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HEMODYNAMICS; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CIRCULATION; MIDDLE AGED;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; BENZIMIDAZOLES; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; LOSARTAN; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENAL CIRCULATION; RENIN; TETRAZOLES; VALINE;

EID: 0036380141     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050213766     Document Type: Article

References (30)

1. Brenner BM, Schor N, Ichikawa I. Role of angiotensin II in the physiologic regulation of glomerular filtration. Am J Cardiol 1982; 49: 1430-3.
2. Rothermund L, Paul M. Hypertension and the renin-angiotensin system-evidence from genetic and transgenic studies. Basic Res in Cardiol 1998; 93 Suppl 2: 1-6.
3. Ljungman S, et al. Blood pressure and renal function. Acta Med Scand 1980; 208: 17-25.
4. Widgren BR, et al. Blunted renal sodium excretion during acute saline loading in normotensive men with positive family histories of hypertension [see comments]. Am J Hypertens 1991; 4(7 Pt 1): 570-8.
5. Widgren BR, et al. Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension [see comments]. Am J Hypertens 1992; 5: 167-74.
6. Yang G, Wan Y, Zhu Y. Angiotensin II-an important stress hormone. Biol Sign 1996; 5: 1-8.
7. Yang G, Xi ZX, Wan Y, Wang H, Bi G. Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol Sign 1993; 2: 166-72.
8. Conlin P, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2002; 13: 418-26.
9. Morsing P. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 1999; 10 Suppl 11: S248-54.
10. Ojima M, et al. Candesartan (CV- 11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319: 137-46.
11. Morsing P, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-13.
12. Anonymous. Benefits of valsartan-hypertension and beyond. Cardiol 1999; 91 Suppl 1: 1-2.
13. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9.
14. Delacretaz E, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
15. Heuer HJ, Schondorfer G, Hogemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 Suppl 2: S55-6.
16. Andersson OK, et al. Organisation and efficacy of an outpatient clinic. Acta Med Scand 1978; 203: 391-8.
17. Ljungman S, Granerous G. The evaluation of kidney function in hypertensive patients. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management, second edition. New York: Raven Press, 1995.
18. Schnurr E, Lahme W, Küppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980; 13: 26-9.
19. Brun C. A rapid method for the determination of paraaminohippurate acid in kidney function test. J Lab Clin Med 1951; 37: 955-8.
20. Kappelgaard R. Damkjaer Nielsen M, Giese J. Measurement of angiotensin II in human plasma: technical modification and practical experience. Clin Chem Acta 1976; 67: 299-306.
21. Morton JJ, Webb DJ. Measurement of plasma angiotensin. Clin Sci 1985; 8: 483-4.
22. Ikeda I, et al. Measurement of plasma renin activity by a simple solid phase radioimmunoassay. J Clin End Met 1982; 54: 423.
23. Malvano R, et al. Recent trends in methodological simplification of steroid radioimmunoassay. Horm Res 1978; 9: 422-39.
24. Kaplan L. Cathecolamines-plasma. Toronto: Mosby, 1987.
25. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens 1999; 12: 1181-7.
26. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hypertens 1999; 13: 275-81.
27. Fridman K, et al. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998; 54: 497-501.
28. Fridman K, Wysocki M, Andersson OK, Friberg P. Candesartan cilexetil in Hypertension: effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin aldosterone system. Blood Press 1999; 8: 242-7.
29. Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal haemodynamics in hypertensive patients. Am J Hypertens 2000; 13: 1045-8.
30. Azizi M, Chatellier G, Guyene TT, Menard J. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. J Hypertens 1999; 17: 561-8.